Takeda Pharmaceutical Company （TAK）2020财年20-F年度报告「NYSE」.pdf

1、As filed with the Securities and Exchange Commission on June 29,2021UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549_FORM 20-F_ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR 12(g)OF THE SECURITIES EXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SEC

2、URITIES EXCHANGE ACT OF 1934For the fiscal year ended March 31,2021 ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to ORSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Date of event req

3、uiring this shell company reportCommission file number:001-38757_Takeda Yakuhin Kogyo Kabushiki Kaisha(Exact name of registrant as specified in its charter)_Takeda Pharmaceutical Company Limited(Translation of registrants name into English)_Japan1-1,Nihonbashi-Honcho 2-ChomeChuo-ku,Tokyo 103-8668,Ja

4、pan(Jurisdiction of incorporation or organization)(Address of principal executive offices)Costa Saroukos 1-1,Nihonbashi-Honcho 2-Chome Chuo-ku,Tokyo 103-8668,Japan Tel:+81 3 3278-2306 Fax:+81 3 3278-2268 Email:Global.External.R(Name,Telephone,E-mail and/or Facsimile number and Address of Company Con

5、tact Person)_Securities registered or to be registered pursuant to Section 12(b)of the Act:Title of Each ClassTrading SymbolsName of Each Exchange On Which Registered American Depositary Shares Representing Common Stock Common Stock,no par value*TAKNew York Stock Exchange0.750%Senior Notes due 2027T

6、AK27New York Stock Exchange1.000%Senior Notes due 2029TAK29New York Stock Exchange1.375%Senior Notes due 2032TAK32New York Stock Exchange2.000%Senior Notes due 2040TAK40ANew York Stock Exchange*Listed not for trading,but only in connection with the registration of the American Depositary Shares,purs